EFFECT OF SHILAJIT ON EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASE IN RATS


NEELIMA S., NARESH BABU T., PRADEEP KUMAR M.

Abstract


Objective: Inflammatory bowel disease (IBD) is a chronic condition of the intestine with unknown etiology involving multiple immunes, genetic and environmental factors. Oxidative stress is believed to be a key factor in the pathogenesis and perpetuation of the mucosal damage in IBD. The present study is to elucidate the effects of shilajit extract on the extent and severity of enterocolitis induced by subcutaneous administration of Indomethacin (7.5 mg/kg b. w) in Wistar rats.

Methods: Study comprised of 6 groups (n=6), normal vehicle control, indomethacin-induced (7.5 mg/kg, 2days), shilajit alone 50 mg/kg b. w, shilajit treated groups (25 and 50 mg/kg, p. o) and sulfasalazine treated (100 mg/kg, p. o) groups. Drug treatment continued for 11 d and on 12th d scarification was done. The colonic mucosal injury was assessed by macroscopic scoring, biochemical (LDH, MPO, GSH and LPO) tests were performed.

Results: Pretreatment with shilajit showed a decrease in macroscopic scores, LDH, MPO, LPO and elevation levels of GSH as compared to the indomethacin-treated group.

Conclusion: The present study suggests that the protective effect of shilajit in indomethacin-induced enterocolitis might be attributed to its scavenging effect on oxygen-derived free radicals and may be beneficial in patients with inflammatory bowel disease.


Keywords


Inflammatory bowel disease, Shilajit, Indomethacin, Subcutaneous

| PDF |

References


The shilajit and SLZ treated groups showed lower scores compared to Indo alone treated group. An elevation of LDH in serum indicates a shift towards anaerobiosis resulting in the enhanced production of lactic acid. In the present study, serum LDH levels were significantly elevated due to Indo administration compared to normal animals. Pre-treatment with shilajit and SLZ inhibited the elevation of serum LDH level.

MPO is a biochemical marker of neutrophil infiltration in the damaged tissue. In Indo alone treated animals, the MPO activity was significantly elevated. This increase in MPO activity was substantially attenuated in rats pre-treated with shilajit and SLZ. (table 1 and fig. 1)

Antioxidants constitute the foremost defence system that limits the toxicity associated with free radicals. The equilibrium between antioxidants and free radicals is an important process for the effective removal of oxidative stress in intracellular organelles. However, in pathological conditions like enterocolitis, the generation of ROS, lipid peroxidation can dramatically upset this balance with an increased demand on the antioxidant defence system. Present study shows Indo causes increased levels in lipid peroxidation while GSH levels decreased. Pre-treatment of rats with shilajit significantly afforded protection against Indo induced increase of intestinal MDA contents. While the antioxidant power of cell such as GSH content was significantly preserved. (table 2 and fig. 2) The protective effect of shilajit is associated with its antioxidant properties, as it acts as ROS scavenger and an inhibitor of lipid peroxidation.

CONCLUSION

In conclusion, the present study demonstrates that shilajit possess protective effects against Indomethacin-induced enterocolitis and the results may be comparable to that of Sulfasalazine. This protective effect may, at least in part, due to its anti-inflammatory and/or antioxidant actions.

CONFLICT OF INTERESTS

Declare none

REFERENCES

Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.

Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007;8:171-8.

Head KA, Jurenka JS. Inflammatory bowel disease part i: ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev 2003;8:247-83.

Hanan HH, Azza EM. Ameliorative effect of pyrrolidine dithiocarbamate on acetic acid induced colitis in rat. Eur J Pharmacol 2007;554:69-77.

Ghosal S, Lal J, Singh SK, Goel RK, Jaiswal AK, Bhattacharya SK. The need for formulation of shilajit by its isolated active constituents. Phytother Res 1991b;5:211-6.

Roth MP, Petersen GM, McElree C. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology 1989;97:900–4.

Yamada T, Deitch E, Specian RD, Perry MA, Sartor B, MB Grisham. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641-62.

Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.

Jagtap AG, Shirke SS, Phadke AS. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J Ethnopharmacol 2004;90:195-204.

Ellman GI. Tissue sulfahydral groups. Arch Biochem Biophys 1957;80:70-7.

Gwlvan G, Saltman P. Different cellular targets of Cu and Fe Catalysed Oxidation observed using a Cu compatible thiobarbiturate acid assay. Biochemica Biophysica Acta 1990;1035:356-60.




About this article

Title

EFFECT OF SHILAJIT ON EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASE IN RATS

Keywords

Inflammatory bowel disease, Shilajit, Indomethacin, Subcutaneous

Date

09-06-2017

Additional Links

Manuscript Submission

Journal

International Journal of Current Pharmaceutical Research
Article in press [Scheduled in July, 2017] Page:

Online ISSN

0975-7066

Statistics

2 Views | 2 Downloads

Authors & Affiliations

NEELIMA S.
Department of Pharmacology, Vasavi Institute of Pharmaceutical Sciences, Kadapa

NARESH BABU T.
Department of Pharmacology, Vasavi Institute of Pharmaceutical Sciences, Kadapa

PRADEEP KUMAR M.
Department of Pharmacology, Vasavi Institute of Pharmaceutical Sciences, Kadapa


Refbacks

  • There are currently no refbacks.